Shield Therapeutics PLC
LSE:STX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shield Therapeutics PLC
Cash from Operating Activities
Shield Therapeutics PLC
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shield Therapeutics PLC
LSE:STX
|
Cash from Operating Activities
-£3.4m
|
CAGR 3-Years
43%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
2%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Operating Activities
£7.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
12%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Operating Activities
$14.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
25%
|
CAGR 10-Years
16%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Operating Activities
$436m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
2%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Cash from Operating Activities
-£32.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-24%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Cash from Operating Activities
£38.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
Shield Therapeutics PLC
Glance View
Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear and currently employs 16 full-time employees. The company went IPO on 2016-02-26. The firm specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The firm's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.
See Also
What is Shield Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
-3.4m
GBP
Based on the financial report for Dec 31, 2025, Shield Therapeutics PLC's Cash from Operating Activities amounts to -3.4m GBP.
What is Shield Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
2%
Over the last year, the Cash from Operating Activities growth was 50%. The average annual Cash from Operating Activities growth rates for Shield Therapeutics PLC have been 43% over the past three years , -19% over the past five years , and 2% over the past ten years .
